Medicaid Pharmacy and Therapeutics Committee Agenda for November 10, 2006
The Pharmacy & Therapeutics Committee will meet November 10, 2006, from 8:45 a.m. to 3:00 p.m., Meeting Room 6, Concourse, Empire State Plaza, Albany, New York
Agenda Items:
- Identification of preferred drugs in the therapeutic class of Anti-Fungals (used in the treatment of Onychomycosis)
- Description: The Committee will review the following drugs to determine preferred and non-preferred status.
- Drug(s) Affected: Fulvicin U/F (griseofulvin), Grifulvin V (griseofulvin), Gris-PEG (griseofulvin), griseofulvin, Lamisil (terbinafine), Penlac (ciclopirox), itraconazole, Sporanox (itraconazole)
- Identification of preferred drugs in the therapeutic class of Anti-Virals (used in the treatment of Herpes)
- Description: The Committee will review the following drugs to determine preferred and non-preferred status.
- Drug(s) Affected: acyclovir, Famvir (famciclovir), Valtrex (valacyclovir), Zovirax (acyclovir)
-
Identification of preferred drugs in the therapeutic class of Fluoroquinolones (Oral)
- Description: The Committee will review the following drugs to determine preferred and non-preferred status.
- Drug(s) Affected: Avelox (moxifloxacin), ciprofloxacin, ofloxacin, Cipro (ciprofloxacin), Cipro XR (ciprofloxacin ER), Factive (gemifloxacin), Floxin (ofloxacin), Levaquin (levofloxacin), Maxaquin (lomefloxacin), Noroxin (norfloxacin), Proquin XR (ciprofloxacin), Tequin (gatifloxacin)
- Review of Prior Authorization Criteria for Serostim
- Description: The Committee will review the current clinical criteria used in the prior authorization process for Serostim.
- Drug(s) Affected: Serostim (somatropin)
- Identification of preferred drugs in the therapeutic class of Third Generation Cephalosporins
- Description: The Committee will review the following drugs to determine preferred and non-preferred status.
- Drug(s) Affected: Cedax (ceftibuten), cefpodoxime proxetil, Omnicef (cefdinir), Suprax (cefixime), Spectracef (cefditoren), Vantin (cefpodoxime proxetil)
Time | Agenda |
---|---|
8:45 - 9:00 | Welcome and Introductions |
9:00 - 10:00 | Comments from interested parties* |
10:00 - 10:20 | Clinical Review of Anti-Fungals |
10:20 - 10:40 | Clinical Review of Anti-Virals |
11:00 - 11:30 | Clinical Review of Fluoroquinolones |
11:30 - 12:30 | Lunch Break/Executive Session (evaluation of trade secret supplemental rebate information) |
12:30 - 12:45 | Final Recommendations for preferred drugs (Anti-Fungals, Anti-Virals, Fluoroquinolones) |
12:45 - 1:45 | Review and Recommendations regarding Serostim Prior Authorization Criteria |
1:45 - 2:15 | Clinical Review of Third Generations Cephalosporins |
2:15 - 2:45 | Afternoon Break/Executive Session (evaluation of trade secret supplemental rebate information) |
2:45 - 2:55 | Final Recommendations for preferred drugs (Cephalosporins) |
2:55 - 3:00 | DOH Update, Final Comments and Adjournment |
*Interested parties must notify DOH at least 72 hours in advance of their request to speak at the committee meeting. Requests may be made by calling 518-486-3209 or e-mailing ppno@health.state.ny.us (please reference P&TCommittee). Public comments are limited to the specific topics on the agenda, must be brief (2 minutes), and the total comment period will not exceed one (1) hour. Written comments regarding topics before the Committee may also be submitted but must be received at least 72 hours in advance of the meeting. Written comments should summarize key points and may not exceed two pages in length. NOTE: Those wishing to submit a clinical study or a clinical report, rather than comments, must submit the study at least two weeks prior to the date of the meeting in order to allow sufficient time for the Committee to review this type of material. If such material is submitted after this time, it cannot be considered by the Committee.
Posted October 6, 2006
Revised November 7, 2006 - Prior Authorization of Topical Immunomodulators agenda item removed